Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Complex regional pain syndrome (CRPS) is a chronic pain condition that most often affects one limb usually after an injury. Symptoms include stiffness in affected joints, changes in nail and hair growth patterns, dystonia, and abnormal sweating pattern. Treatment includes bisphosphonates, non-steroidal anti-inflammatory drugs, opioids, and local anesthetic creams.

The Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) Drugs in Development market research report provides an overview of the Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) and features dormant and discontinued projects.

CRPS Pipeline Drugs Market Targets

The targets of the CRPS pipeline drugs market are Glutamate Ionotropic Receptor NMDA Type Subunit, Cannabinoid Receptor 2, Cannabinoid Receptor 1, Neuronal Acetylcholine Receptor Subunit Alpha 7, Synaptosomal Associated Protein 25, and Toll Like Receptor 4.

CRPS pipeline drugs market, by targets

CRPS pipeline drugs market, by targets

For more target insights, download a free report sample

Mechanisms of Action of CRPS Pipeline Drugs Market

The mechanisms of action of the CRPS pipeline drugs market are Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist, Cannabinoid Receptor 2 Agonist, Cannabinoid Receptor 1 Agonist, Neuronal Acetylcholine Receptor Subunit Alpha 7 Antagonist, Synaptosomal Associated Protein 25 Inhibitor, and Toll Like Receptor 4 Antagonist.

CRPS pipeline drugs market, by mechanisms of action

CRPS pipeline drugs market, by mechanisms of action

For more mechanisms of action insights, download a free report sample

Routes of Administration in CRPS Pipeline Drugs Market

The routes of administration in the CRPS pipeline drugs market are inhalational, oral, subcutaneous, intraarticular, intradermal, intramuscular, intraprostatic, parenteral, sublingual, and topical.

CRPS pipeline drugs market, by routes of administration

CRPS pipeline drugs market, by routes of administration

For more routes of administration insights, download a free report sample

Molecule Types in CRPS Pipeline Drugs Market

The molecule types in the CRPS pipeline drugs market are small molecule and protein.

CRPS pipeline drugs market, by molecule types

CRPS pipeline drugs market, by molecule types

For more molecule type insights, download a free report sample

Key CRPS Pipeline Drugs Market Companies

Some of the key companies in the CRPS pipeline drugs market are Tetra Bio-Pharma Inc, AbbVie Inc, Bexson Biomedical Inc, Bio-Pharm Solutions Co Ltd, Biohaven Pharmaceutical Holding Company Ltd, iX Biopharma Ltd, NeuroTherpia Inc, PharmaTher Holdings Ltd, Soin Therapeutics LLC, and Tryp Therapeutics Inc.

CRPS pipeline drugs market, by key companies

CRPS pipeline drugs market, by key companies

To know more about key companies, download a free report sample

Market report overview

Targets Glutamate Ionotropic Receptor NMDA Type Subunit, Cannabinoid Receptor 2, Cannabinoid Receptor 1, Neuronal Acetylcholine Receptor Subunit Alpha 7, Synaptosomal Associated Protein 25, and Toll Like Receptor 4
Mechanisms of Action Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist, Cannabinoid Receptor 2 Agonist, Cannabinoid Receptor 1 Agonist, Neuronal Acetylcholine Receptor Subunit Alpha 7 Antagonist, Synaptosomal Associated Protein 25 Inhibitor, and Toll Like Receptor 4 Antagonist
Routes of Administration Inhalational, Oral, Subcutaneous, Intraarticular, Intradermal, Intramuscular, Intraprostatic, Parenteral, Sublingual, and Topical
Molecule Types Small Molecule and Protein
Key Companies Tetra Bio-Pharma Inc, AbbVie Inc, Bexson Biomedical Inc, Bio-Pharm Solutions Co Ltd, Biohaven Pharmaceutical Holding Company Ltd, iX Biopharma Ltd, NeuroTherpia Inc, PharmaTher Holdings Ltd, Soin Therapeutics LLC, and Tryp Therapeutics Inc

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of Complex Regional Pain Syndrome (Central Nervous System).
  • Reviews of pipeline therapeutics for Complex Regional Pain Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Reviews of key companies involved in Complex Regional Pain Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • Evaluation of Complex Regional Pain Syndrome (Central Nervous System) targeted therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news and deals related to pipeline therapeutics for Complex Regional Pain Syndrome (Central Nervous System).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Complex Regional Pain Syndrome (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Complex Regional Pain Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

AbbVie Inc
Bexson Biomedical Inc
Bio-Pharm Solutions Co Ltd
Biohaven Pharmaceutical Holding Company Ltd
iX Biopharma Ltd
NeuroTherpia Inc
PharmaTher Holdings Ltd
Soin Therapeutics LLC
Tetra Bio-Pharma Inc
Tryp Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) – Overview

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) – Companies Involved in Therapeutics Development

AbbVie Inc

Bexson Biomedical Inc

Bio-Pharm Solutions Co Ltd

Biohaven Pharmaceutical Holding Company Ltd

iX Biopharma Ltd

NeuroTherpia Inc

PharmaTher Holdings Ltd

Soin Therapeutics LLC

Tetra Bio-Pharma Inc

Tryp Therapeutics Inc

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) – Drug Profiles

ADD-457023 – Drug Profile

Product Description

Mechanism Of Action

BHV-5000 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ketamine – Drug Profile

Product Description

Mechanism Of Action

History of Events

ketamine – Drug Profile

Product Description

Mechanism Of Action

History of Events

ketamine – Drug Profile

Product Description

Mechanism Of Action

History of Events

naltrexone – Drug Profile

Product Description

Mechanism Of Action

History of Events

NTRX-07 – Drug Profile

Product Description

Mechanism Of Action

onabotulinumtoxin A – Drug Profile

Product Description

Mechanism Of Action

History of Events

PPP-001 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules for Pain – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System – Drug Profile

Product Description

Mechanism Of Action

TRP-8803 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) – Dormant Projects

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) – Discontinued Products

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) – Product Development Milestones

Featured News & Press Releases

Dec 27, 2021: Soin Therapeutics completes formulation development of novel low dose naltrexone tablet to treat complex regional pain syndrome

Oct 21, 2021: Tetra Bio-Pharma receives positive opinion for orphan drug designation for QIXLEEF from the European Medicines Agency

Oct 13, 2021: PharmaTher granted FDA orphan drug designation for ketamine to treat complex regional pain syndrome

Sep 09, 2021: FDA grants orphan drug status to Soin Therapeutics for low dose naltrexone (LDN) to treat complex regional pain syndrome (CRPS)

Apr 29, 2021: Bexson Biomedical granted USPTO patent on proprietary Ketamine formulation

Oct 08, 2019: Bexson Biomedical’s Chief Scientific Officer speaks to ketamine leaders at ASKP conference

Feb 05, 2019: Tetra Bio-Pharma redefines quality standards for pharmaceutical grade cannabis-derived products

Mar 14, 2018: Tetra Bio-Pharma Announces FDA Orphan Drug Designation for PPP001 in Treatment of Complex Regional Pain Syndrome

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) – Pipeline by AbbVie Inc, 2022

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) – Pipeline by Bexson Biomedical Inc, 2022

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) – Pipeline by Bio-Pharm Solutions Co Ltd, 2022

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) – Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2022

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) – Pipeline by iX Biopharma Ltd, 2022

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) – Pipeline by NeuroTherpia Inc, 2022

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) – Pipeline by PharmaTher Holdings Ltd, 2022

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) – Pipeline by Soin Therapeutics LLC, 2022

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) – Pipeline by Tetra Bio-Pharma Inc, 2022

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) – Pipeline by Tryp Therapeutics Inc, 2022

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) – Dormant Projects, 2022

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy), 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.